Trial Information

Effect of Radioactive Iodine on Eradication of Helicobacter Pylori in Patients Treated for Thyroid Diseases

Objective To test eradicate H.pylori after administration of radioactive iodine (131I) to
patients with thyroid diseases and to evaluate their H.pylori CagA status .

Design Observational study

Setting

The Isotopic Institute at the Rabin Medical Center, Campus Beilinson Patients Consecutive
patients with thyroid diseases referred to the Isotopic Institute at the Rabin Medical
Center, Campus Beilinson for either radioactive iodine (131I) thyroid scan or radioactive
iodine (131I)treatment for their disease, will be screened, prior to the radioactive
iodine, for H. pylori infection and CagA protein by serology. Patient with positive
serology for H. pylori will be tested for active gastric infection using the H.pylori stool
antigen test. The study population will include all patients who tested positive for
H.pylori both by serology and stool antigen tests. Six to eight weeks and 6 month after
administration of radioactive iodine (131I) treatment , stool antigen or H.pylori will be
tested again to confirm persistence of H.pylori eradication.

Main Outcome Measure confirmed H.pylori eradication by the stool antigen test. The rate of
infection with virulent and caricogenic CagA H.pylori ,will be tested using the immunoblot
assay.

Summary

We will test in this study whether Helicobacter pylori is eradicated, after radioactive
iodine (131I) administration, from the stomach of patients with thyroid diseases. The rate
of CagA virulent and carcinogenic H.pylori infection in theses patients will be assessed.